TNSN00253A1 - Forme posologique de medicament a liberation controlee - Google Patents
Forme posologique de medicament a liberation controleeInfo
- Publication number
- TNSN00253A1 TNSN00253A1 TNTNSN00253A TNSN00253A TNSN00253A1 TN SN00253 A1 TNSN00253 A1 TN SN00253A1 TN TNSN00253 A TNTNSN00253 A TN TNSN00253A TN SN00253 A TNSN00253 A TN SN00253A TN SN00253 A1 TNSN00253 A1 TN SN00253A1
- Authority
- TN
- Tunisia
- Prior art keywords
- dosage form
- controlled release
- core
- release medicine
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L’INVENTION CONCERNE UNE FORME POSOLOGIQUE A LIBERATION CONTROLEE (10). CETTE FORME POSOLOGIQUE COMPREND UN NOYAU (12) COMPRENANT UNE COMPOSITION CONTENANT UN MEDICAMENT (14) ET UNE COMPOSITION POUVANT GONFLER DANS L’EAU (16), CHACUNE OCCUPANT DES REGIONS DISTINCTES DANS LE NOYAU. LA COMPOSITION CONTENANT UN MEDICAMENT A FAIBLE SOLUBILITE ET UN AGENT D’ENTRAINEMENT DE MEDICAMENT. L’ENROBAGE (18) AUTOUR DU NOYAU EST PERMEABLE A L’EAU ET INSOLUBLE DANS L’EAU ET COMPORTE AU MOINS UN ORIFICE DE LIBERATION. APPLICATION : TRAITEMENT DE DIVERSES AFFECTIONS AVEC UN MEDICAMENT DANS UNE TELLE FORME POSOLOGIQUE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17196899P | 1999-12-23 | 1999-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN00253A1 true TNSN00253A1 (fr) | 2002-05-30 |
Family
ID=22625827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN00253A TNSN00253A1 (fr) | 1999-12-23 | 2000-12-22 | Forme posologique de medicament a liberation controlee |
Country Status (42)
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200100039A (es) | 2000-03-16 | 2001-12-31 | Pfizer | Inhibidor de la glucogeno fosforilasa. |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US20100196466A1 (en) * | 2000-06-06 | 2010-08-05 | Capricorn Pharma Inc. | Drug delivery system |
US7678387B2 (en) * | 2000-06-06 | 2010-03-16 | Capricorn Pharma, Inc. | Drug delivery systems |
US20070059367A1 (en) * | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CA2450748A1 (fr) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Compositions pharmaceutiques contenant des ensembles polymere et medicament |
EP1414458B1 (fr) | 2001-07-06 | 2007-04-11 | Endo Pharmaceuticals Inc. | Administration orale de 6-hydroxy-oxymorphone utilise en tant qu'analgesique |
WO2003063833A1 (fr) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles |
WO2003063868A1 (fr) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester |
AU2003269744A1 (en) * | 2002-05-15 | 2003-12-02 | Sun Pharmaceutical Industries Limited | Oral osmotic controlled drug delivery system |
US20040076668A1 (en) * | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
WO2004050068A1 (fr) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Compositions pharmaceutiques comprenant un compose medicamenteux respectivement basique, tensioactif et base respectivement acide hydrosoluble et tolerable physiologiquement |
EP1596837A2 (fr) * | 2003-02-07 | 2005-11-23 | Omega Farma Ehf | Formules de venlafaxine a liberation prolongee |
EP1622591A1 (fr) * | 2003-05-06 | 2006-02-08 | Ranbaxy Laboratories, Ltd. | Liberation biphasique de glipizide contenu dans une forme pharmaceutique osmotique monocompartiment |
JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
CA2537413A1 (fr) * | 2003-09-02 | 2005-03-10 | Imran Ahmed | Formes posologiques a liberation prolongee de ziprasidone |
WO2006045152A1 (fr) * | 2004-10-29 | 2006-05-04 | Mayne Pharma International Pty Ltd | Procede ameliore de preparation de comprimes |
WO2006072878A1 (fr) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Formes posologiques orales de sertraline possedant une taille de particule controlee, et leurs procedes de preparation |
GB0504547D0 (en) * | 2005-03-04 | 2005-04-13 | Delsol Products Ltd | Personal lubricant |
EP1858493A4 (fr) * | 2005-03-14 | 2010-12-01 | Sun Pharmaceutical Ind Ltd | Systeme d'administration de medicament par voie orale |
US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
US7541347B2 (en) | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7544373B2 (en) * | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
WO2007057762A2 (fr) * | 2005-11-16 | 2007-05-24 | Pfizer Limited | Forme posologique a liberation controlee |
US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
CN101439026B (zh) * | 2007-11-23 | 2011-04-06 | 北京红林制药有限公司 | 含有多沙唑嗪或其盐的控释制剂及其制备方法 |
CA2715584A1 (fr) * | 2008-02-15 | 2009-10-08 | Sun Pharma Advanced Research Company Ltd. | Comprime oral a liberation controlee |
KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
KR101284368B1 (ko) | 2010-07-09 | 2013-07-15 | 서울대학교산학협력단 | 나노섬유시트 기재의 경구용 약물의 제어 전달을 위한 시스템 |
WO2012103411A2 (fr) * | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Composition de mélatonine à libération contrôlée et procédés associés |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
DK2950822T3 (da) * | 2013-01-30 | 2019-07-22 | Daewoong Co Ltd | Farmaceutisk sammensætning til beskyttelse af sår, tilvejebringelse af hæmostase eller forebyggelse af adhæsion i mave-tarm-kanalen |
NZ711225A (en) | 2013-03-14 | 2020-06-26 | Amgen Inc | A pharmaceutical formulation comprising omecamtiv mecarbil, processess and uses |
JP6634368B2 (ja) * | 2013-03-14 | 2020-01-22 | アムジエン・インコーポレーテツド | 複素環式化合物及びそれらの使用 |
US20170182070A1 (en) | 2014-10-08 | 2017-06-29 | Mayne Pharma International Pty Ltd. | Controlled Release Doxycycline |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
EP3340982B1 (fr) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Composés pour le traitement de troubles immunitaires et inflammatoires |
AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
CN113365617A (zh) | 2018-10-16 | 2021-09-07 | 乔治亚州立大学研究基金会股份有限公司 | 用于医学疾病治疗的一氧化碳前药 |
JP2023533420A (ja) * | 2020-07-10 | 2023-08-03 | アデア ファーマシューティカルズ,インコーポレイテッド | 膨潤性経口医薬組成物 |
JP2023541997A (ja) | 2020-09-18 | 2023-10-04 | ブリストル-マイヤーズ スクイブ カンパニー | 膨潤性コアを含むtyk2阻害薬の剤形 |
TW202325285A (zh) * | 2021-10-14 | 2023-07-01 | 靜岡縣公立大學法人 | 粉末製劑 |
WO2023154171A1 (fr) * | 2022-02-14 | 2023-08-17 | Purdue Research Foundation | Sels polymères destinés à améliorer l'administration de médicament à partir de dispersions solides amorphes |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
IT1165797B (it) * | 1982-10-18 | 1987-04-29 | Consiglio Nazionale Ricerche | Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US5082668A (en) * | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
GB8322007D0 (en) * | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
US4624848A (en) * | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US4865598A (en) * | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
EP0277092B1 (fr) * | 1987-01-14 | 1992-01-29 | Ciba-Geigy Ag | Système thérapeutique pour médicaments peu solubles |
US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4795641A (en) * | 1987-08-20 | 1989-01-03 | Eastman Kodak Company | Polymer blends having reverse phase morphology for controlled delivery of bioactive agents |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
US5096716A (en) * | 1988-09-01 | 1992-03-17 | Alza Corporation | Dosage form for administering calcium antagonist nicardipine |
US5110596A (en) * | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5186942A (en) * | 1989-01-30 | 1993-02-16 | Alza Corporation | Nicardipine therapy |
DD295760A5 (de) * | 1989-01-31 | 1991-11-14 | Martin-Luther-Universitaet Halle Wittenberg,De | Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung |
US5019396A (en) * | 1989-05-12 | 1991-05-28 | Alza Corporation | Delivery dispenser for treating cardiac arrhythmias |
US5776493A (en) * | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
US5126142A (en) * | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5273752A (en) * | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5091190A (en) * | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US5035897A (en) * | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5200197A (en) * | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
US5151450A (en) * | 1990-02-22 | 1992-09-29 | Tokyo Tanabe Company, Limited | Antiulcer substance |
US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5128145A (en) * | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
ATE106015T1 (de) * | 1990-09-28 | 1994-06-15 | Pfizer | Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält. |
US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
ZA927779B (en) * | 1991-10-10 | 1993-07-05 | Alza Corp | Osmotic drug delivery devices with hydrophobic wall materials. |
US5200195A (en) * | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
US5185158A (en) * | 1992-02-27 | 1993-02-09 | Alza Corporation | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same |
HU226456B1 (en) * | 1992-09-18 | 2008-12-29 | Astellas Pharma Inc | Sustained-release hydrogel preparation |
US5358721A (en) * | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
DK0621032T3 (da) * | 1993-04-23 | 2000-10-23 | Novartis Ag | Lægemiddelform med reguleret afgivelse |
US6287598B1 (en) * | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
GB9326267D0 (en) * | 1993-12-23 | 1994-02-23 | Scherer Corp R P | Expulsion of material |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5458888A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US6068859A (en) * | 1994-05-06 | 2000-05-30 | Pfizer Inc. | Controlled-release dosage forms of Azithromycin |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5529787A (en) * | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
US5582591A (en) * | 1994-09-02 | 1996-12-10 | Delab | Delivery of solid drug compositions |
US5718700A (en) * | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
US5614578A (en) * | 1994-10-28 | 1997-03-25 | Alza Corporation | Injection-molded dosage form |
US5607696A (en) * | 1995-02-10 | 1997-03-04 | Alza Corporation | Osmotic membrane and delivery device |
US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5817335A (en) * | 1995-05-26 | 1998-10-06 | Alza Corporation | Osmotic device with high drug loading and delayed activation of drug delivery |
US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
FR2744733B1 (fr) * | 1996-02-08 | 1998-04-24 | Ascometal Sa | Acier pour la fabrication de piece forgee et procede de fabrication d'une piece forgee |
IT1290764B1 (it) * | 1996-05-03 | 1998-12-10 | Vevy Europ S P A | Pentapeptide per la preparazione di composizioni dermo- farmaceutiche e cosmetiche per il trattamento di lesioni od affezioni cutanee |
US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
US6271278B1 (en) * | 1997-05-13 | 2001-08-07 | Purdue Research Foundation | Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties |
IL128043A (en) * | 1997-05-30 | 2004-08-31 | Osmotica Corp | Multi-layered osmotic device for controlled delivery of active agents |
PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
DE19737463A1 (de) * | 1997-08-28 | 1999-03-04 | Hoechst Marion Roussel De Gmbh | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
DE60042352D1 (de) * | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
US6245200B1 (en) | 1999-12-10 | 2001-06-12 | Sandia Corporation | Photo-oxidation method using MoS2 nanocluster materials |
CA2395231C (fr) * | 1999-12-23 | 2006-08-15 | Pfizer Products Inc. | Forme de dosage d'un medicament stratifie entraine par un hydrogel |
US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
-
2000
- 2000-12-20 EP EP08154885A patent/EP1967185A1/fr not_active Withdrawn
- 2000-12-20 PL PL00357535A patent/PL357535A1/xx not_active Application Discontinuation
- 2000-12-20 SI SI200030997T patent/SI1242055T1/sl unknown
- 2000-12-20 OA OA1200200195A patent/OA12128A/en unknown
- 2000-12-20 KR KR10-2002-7008223A patent/KR100523127B1/ko not_active IP Right Cessation
- 2000-12-20 JP JP2001548095A patent/JP4100910B2/ja not_active Expired - Fee Related
- 2000-12-20 BR BR0016708-8A patent/BR0016708A/pt not_active Application Discontinuation
- 2000-12-20 DZ DZ003228A patent/DZ3228A1/fr active
- 2000-12-20 EE EEP200200361A patent/EE200200361A/xx unknown
- 2000-12-20 GE GE4830A patent/GEP20043334B/en unknown
- 2000-12-20 IL IL14922400A patent/IL149224A0/xx unknown
- 2000-12-20 AT AT00983435T patent/ATE392890T1/de not_active IP Right Cessation
- 2000-12-20 ES ES00983435T patent/ES2302705T3/es not_active Expired - Lifetime
- 2000-12-20 WO PCT/IB2000/001920 patent/WO2001047500A1/fr active IP Right Grant
- 2000-12-20 YU YU35302A patent/YU35302A/sh unknown
- 2000-12-20 DE DE60038698T patent/DE60038698T2/de not_active Expired - Lifetime
- 2000-12-20 EA EA200200595A patent/EA004370B1/ru not_active IP Right Cessation
- 2000-12-20 EP EP00983435A patent/EP1242055B1/fr not_active Expired - Lifetime
- 2000-12-20 HU HU0301242A patent/HUP0301242A3/hu unknown
- 2000-12-20 CN CN00816441A patent/CN1402632A/zh active Pending
- 2000-12-20 PT PT00983435T patent/PT1242055E/pt unknown
- 2000-12-20 US US09/745,095 patent/US20020015731A1/en not_active Abandoned
- 2000-12-20 AU AU20189/01A patent/AU783685B2/en not_active Ceased
- 2000-12-20 CZ CZ20022046A patent/CZ20022046A3/cs unknown
- 2000-12-20 AP APAP/P/2002/002553A patent/AP2002002553A0/en unknown
- 2000-12-20 CA CA002395333A patent/CA2395333C/fr not_active Expired - Fee Related
- 2000-12-20 MX MXPA02006328A patent/MXPA02006328A/es active IP Right Grant
- 2000-12-20 DK DK00983435T patent/DK1242055T3/da active
- 2000-12-20 NZ NZ518281A patent/NZ518281A/en unknown
- 2000-12-20 SK SK857-2002A patent/SK8572002A3/sk unknown
- 2000-12-20 TR TR2002/01646T patent/TR200201646T2/xx unknown
- 2000-12-21 GT GT200000222A patent/GT200000222A/es unknown
- 2000-12-22 AR ARP000106897A patent/AR027091A1/es unknown
- 2000-12-22 PE PE2000001391A patent/PE20010985A1/es not_active Application Discontinuation
- 2000-12-22 TN TNTNSN00253A patent/TNSN00253A1/fr unknown
- 2000-12-22 SV SV2000000250A patent/SV2002000250A/es unknown
- 2000-12-22 PA PA20008509001A patent/PA8509001A1/es unknown
-
2002
- 2002-04-12 IS IS6340A patent/IS6340A/is unknown
- 2002-06-04 CR CR6656A patent/CR6656A/es unknown
- 2002-06-18 MA MA26695A patent/MA26859A1/fr unknown
- 2002-06-20 ZA ZA200204960A patent/ZA200204960B/en unknown
- 2002-06-20 NO NO20022970A patent/NO20022970L/no not_active Application Discontinuation
- 2002-06-24 BG BG106865A patent/BG106865A/bg unknown
-
2006
- 2006-12-14 US US11/610,603 patent/US20070087057A1/en not_active Abandoned
-
2010
- 2010-12-27 US US12/979,278 patent/US9028870B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN00253A1 (fr) | Forme posologique de medicament a liberation controlee | |
TNSN01123A1 (fr) | Formes posologiques nouvelles a liberation controlee | |
TNSN01132A1 (fr) | Derives de pyrazole nouveaux et compositions les contenant. | |
TNSN00028A1 (fr) | Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN00252A1 (fr) | Compositions pharmaceutiques engendrant des concentrations accrues de medicaments | |
TNSN96107A1 (fr) | Benzylaminopiperidines substitues et compositions pharmaceutiques les contenant | |
DE69021214D1 (de) | Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten. | |
TNSN01035A1 (fr) | Derives d'ethers de pyrazole nouveaux, et compositions pharmaceutiques les contenant. | |
TNSN00036A1 (fr) | Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN97139A1 (fr) | Derives d'acides d'arylsulfonylaminohydroxamiques | |
TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN00065A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant. | |
GB0025173D0 (en) | Therapeutic agents | |
TNSN00228A1 (fr) | Derives de benzimidazole nouveaux, et compositions les contenant | |
IL173684A0 (en) | Disodium-4,4'-azo-bis-salicylate and pharmaceutical compositions containing the same | |
TNSN00235A1 (fr) | Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
FR2405711A1 (fr) | Composition pharmaceutique contenant de l'amoxycilline et du clavulanate de potassium | |
TNSN00169A1 (fr) | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant | |
TNSN01149A1 (fr) | Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant. | |
BG105173A (en) | Novel salt form of pantoprazole | |
TNSN00108A1 (fr) | Derives d'erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99198A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT | |
BG105302A (en) | Means for improving cognition |